The huge premium drug maker Alexion Pharmaceuticals Inc. is paying for Synageva BioPharma Corp.—$8.4 billion, or more than double Synageva’s market value—shows how hot the market has become for rare-disease drugs.
from WSJ.com: US Business http://ift.tt/1zCozIj
via IFTTT
No comments:
Post a Comment